Can a diabetes drug tame obesity caused by brain tumor treatment?

NCT ID NCT02860923

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether exenatide, a diabetes drug, plus lifestyle changes helps adults with severe weight gain after treatment for a rare brain tumor (craniopharyngioma). 42 adults aged 18-75 took either exenatide or a placebo for 6 months. The main goal was to see if they lost weight. The study also checked for side effects like nausea and injection-site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired hypothalamic obesity craniopharyngioma Sexual Infantilism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRANIOPHARYNGIOMAS HYPOTHALAMIC OBESITY

Contacts and locations

Locations

APHM

Marseille, France
CHU d'Angers

Angers, France
CHU de Brest

Brest, France
CHU de Grenoble

Grenoble, France
CHU de Lyon

Lyon, France
CHU de Toulouse

Toulouse, France
Hôpital Bicêtre

Paris, France
Hôpital Cochin

Paris, France
Hôpital Européen Georges Pompidou

Paris, France
Hôpital Haut-Lévêque

Pessac, France
Hôpital Pitié Salpétrière (APHP)

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.